In this article (Cancer Immunol Res 2014;2:295–300), which appeared in the April 2014 issue of Cancer Immunology Research (1), a virus was named incorrectly under the Oncolytic Viruses section. The corrected sentence is below. The authors regret this error. The online version has been corrected and no longer matches the print.
Oncolytic Viruses
These include autonomous parvoviruses, myxoma virus (MYXV; poxvirus), Newcastle disease virus (NDV; paramyxovirus), reovirus, and Seneca valley virus (SVV; picornavirus); and (ii) viruses that are genetically manipulated for use as vaccine vectors, including measles virus (MV; paramyxovirus), poliovirus (PV; picornavirus), and vaccinia virus (VV; poxvirus), and/or those genetically engineered with mutations/deletions in genes required for replication in normal but not in cancer cells including adenovirus (Ad), herpes simplex virus (HSV), VV, and vesicular stomatitis virus (VSV; rhabdovirus; refs. 1, 3).
- ©2014 American Association for Cancer Research.
Reference
- 1.↵